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Summary
 
The characteristics of CD8
 
1
 
 T cells responsible for memory responses are still largely un-
known. Particularly, it has not been determined whether different activation thresholds distin-
guish naive from memory CD8
 
1
 
 T cell populations. In most experimental systems, heteroge-
neous populations of primed CD8
 
1
 
 T cells can be identified in vivo after immunization. These
cells differ in terms of cell cycle status, surface phenotype, and/or effector function. This heter-
ogeneity has made it difficult to assess the activation threshold and the relative role of these
subpopulations in memory responses. In this study we have used F5 T cell receptor transgenic
mice to generate a homogeneous population of primed CD8
 
1
 
 T cells. In the F5 transgenic
mice, peptide injection in vivo leads to activation of most peripheral CD8
 
1
 
 T cells. In vivo
BrdU labeling has been used to follow primed T cells over time periods spanning several weeks
after peptide immunization. Our results show that the majority of primed CD8
 
1
 
 T cells gener-
ated in this system are not cycling and express increased levels of CD44 and Ly6C. These cells
remain responsive to secondary peptide challenge in vivo as evidenced by short term upregula-
tion of activation markers such as CD69 and CD44. The activation thresholds of naive and
primed CD8
 
1
 
 T cells were compared in vitro. We found that CD8
 
1
 
 T cells from primed mice
are activated by peptide concentrations 10–50-fold lower than naive mice. In addition, the ki-
netics of interleukin 2R
 
a
 
 chain upregulation by primed CD8
 
1
 
 T cells differ from naive CD8
 
1
 
T cells. These primed hyperresponsive CD8
 
1
 
 T cells might play an important role in the mem-
ory response.
 
I
 
mmunological memory is the capacity of the immune
system to respond faster and more efficiently against an
antigen it has encountered in the past. T cell memory is be-
lieved to result from an increase in the frequency of antigen
specific T lymphocytes (1, 2). For CD4
 
1
 
 T cells, a change
in the activation requirements of memory cells has been re-
ported (3, 4). In these studies, memory CD4
 
1
 
 T cells were
identified using different surface markers. However, most
of these markers are also expressed by freshly activated cells,
making it difficult to distinguish memory T cells from acti-
vated T cells. More recent studies have taken advantage of
TCR-transgenic mice. These studies have confirmed that
primed CD4
 
1
 
 T cells are hyperreactive to antigenic stimu-
lation in vitro (5). However, the contribution of this in-
creased reactivity versus that of clonal expansion to the
memory response in vivo is difficult to estimate. Moreover,
it may vary depending on the experimental system.
For CD8
 
1
 
 T cells, it is also well established that the
frequency of precursor CTL increases after antigenic chal-
lenge (1, 6). However, this might not be the only parameter
responsible for the memory response because primed CD8
 
1
 
T cells have also been shown to give a more sustained, al-
beit slower, in vivo response than naive CD8
 
1
 
 T cells (7).
The cell cycle status of memory CD8
 
1
 
 cells is debatable
(8). Few studies have directly measured the proliferation
rate of memory CD8
 
1
 
 T cells. When the life span of T cells
with a “memory” phenotype was measured using BrdU la-
beling, a large fraction divided rapidly, whereas another
fraction remained in interphase for several weeks (9). A
similar dichotomy of cycling versus noncycling cells was
found when the cell cycle status of LCMV memory CTL
precursors was studied (10). Moreover, these two subsets
required different conditions for their activation in vitro.
The relationship between the cycling and the noncycling
memory CTL precursors as well as their relative longevity
has not been studied. They could represent different subsets
or differentiation stages of memory T cells requiring differ-
ent signals for their activation and/or maintenance. The
role played by antigen in the maintenance of memory
CD8
 
1
 
 T cells is still controversial (11–15), but in some ex-
perimental systems maintenance of memory in the absence
of antigen persistence is possible (11–13). However, in
  
2142
 
Generation of Resting, Hyperreactive Memory CD8
 
1
 
 T Cells
 
these conditions it is not known whether memory CTL
precursors also show a heterogeneous phenotype and life
span.
To identify antigen primed CD8
 
1
 
 T cells, we used F5
TCR transgenic mice. The majority of peripheral T cells in
F5 mice are CD8
 
1
 
, and 
 
.
 
95% of these express V
 
b
 
11. In-
traperitoneal injection of influenza virus NP peptide (resi-
dues 366–374) in these mice leads to an increase in the
number of CD8
 
1
 
 spleen T cells. This is paralleled by CD44
upregulation on all CD8
 
1
 
 T cells (16, 17), which also ac-
quire the ability to lyse peptide-pulsed targets cells ex vivo
(16). CD8
 
1
 
 T cells with increased levels of CD44 are still
present in the spleen of thymectomized mice up to 6 wk
after peptide challenge (17).
In this report, we have characterized these primed CD8
 
1
 
T cells with respect to surface antigens, life span and reac-
tivity to antigen in vivo and in vitro. We have used BrdU
to mark cells proliferating in response to antigen during the
primary response. In thymectomized mice, the majority of
BrdU labeled CD8
 
1
 
 T cells are still present several weeks
after immunization. In normal euthymic mice, BrdU la-
beled cells are diluted by naive T cells. However, a fraction
(20%) of BrdU-labeled CD8
 
1
 
 T cells are still present 11 wk
after priming, indicating a long life span. These primed
CD8
 
1
 
 T cells express increased levels of CD44 and Ly6C
when compared with naive CD8
 
1
 
 T cells. Using thymec-
tomized F5 TCR-transgenic mice we show that primed
CD8
 
1
 
 T cells are not anergic as they are responsive to a
second in vivo antigenic challenge. The activation thresh-
old of primed and naive CD8
 
1
 
 T cells was measured in
vitro. We show that, in the presence of IL-2, primed cells
hyperproliferate to all doses of antigen and that their prolif-
eration is triggered at antigen doses 10–50 fold lower than
the one triggering naive cells. For the sake of clarity, we
call CD8
 
1
 
 T cells surviving 
 
.
 
3 wk after immunization
primed cells, opposed to CD8
 
1
 
 T cells that are found dur-
ing the first week after immunization which we call acti-
vated.
 
Materials and Methods
 
Mice and Immunizations.
 
C57BL10 and F5 TCR transgenic
mice were a gift from D. Kioussis (18). All animals were bred in
the institute’s animal facility. Thymectomies were performed on
5–7-wk-old mice, which were then allowed to recover for at
least 4 wk before antigenic challenge. Immunizations were per-
formed by injecting 50 nmol of the A/NT/60/68 influenza virus
nucleoprotein peptide Ala-Ser-Asn-Glu-Asn-Met-Asp-Ala-Met
[NP-(366-374)] (Neosystems Laboratoire, Strasbourg, France) in
PBS into the peritoneal cavity. Control mice were either not
treated or injected with PBS alone.
 
In Vivo BrdU Labeling.
 
Mice were given BrdU (Sigma
Chemicals Co., St. Louis, MO) at 1 mg/ml in drinking water.
The BrdU-containing water was protected from light and changed
daily. Mice were given BrdU for 5 or 7 d, starting 1 d before
peptide injection.
 
Fluorescence Staining and Flow Cytometry Analysis.
 
Spleen cell
suspensions were applied to Ficoll–Hypaque (Lympholyte M;
Cedarlane Laboratories Ltd., Hornby, Canada) gradient centrifu-
gation. Cells were then washed twice with medium, resuspended
in PBS containing 2% horse serum and 0.1% NaN
 
3
 
, and then 10
 
6
 
cells were incubated with antibody for 45 min at 4
 
8
 
C. After two
more washes with PBS/horse serum/NaN
 
3
 
, cells were incubated
in the presence of second layer reagents (avidin-PE or avidin-tri-
color; (CALTAG Laboratories, South San Francisco, CA) for 30
min at 4
 
8
 
C. Cells were washed twice and analyzed on a FACScan
 
Ò
 
(Becton Dickinson & Co., Mountain View, CA). The following
antibodies were used: YTS169.4-PE (anti CD8), IM7.8.1-FITC
(anti CD44), CG16-biotin (anti-CD5) from Caltag Laboratories;
HI.2F3-biotin (anti CD69), Jo2-biotin (anti Fas), 5H4-FITC
(anti–IL2R
 
b
 
), 4G3-PE (anti–IL2R
 
g
 
) from PharMingen (San Diego,
CA); PC61.5.3-biotin (anti–IL2R
 
a
 
) from Cedarlane Laboratories
Ltd.; IM7.8.1-biotin (anti CD44), Mel-14-biotin (anti–l-selectin),
RR3-15-biotin (anti V
 
b
 
11), RA3-2C2-biotin (anti-CD45RA),
23G2-biotin (anti-CD45RB), FD441.8-biotin (anti–LFA-1), YN1/
1.7-biotin (anti–ICAM-1), 145-2C11-FITC (anti CD3), and 143-
4-2-biotin (anti-Ly6.2C) were prepared in house.
Staining for BrdU incorporation was conducted as previously
described (9) with minor modifications. In brief, cells were
stained for surface markers as above, resuspended in cold 0.15 M
NaCl solution, and fixed by injection into cold 95% ethanol.
After a 30 min incubation on ice, cells were washed once with
PBS and resuspended in PBS, 0.01% Tween 20, and 1% para-
formaldehyde. After a 1-h incubation at room temperature, cells
were washed with 0.15 M NaCl, and the DNA was partially di-
gested with DNase I (Appligene, Illkirch, France) in 25 mM
CaCl
 
2
 
, 5mM MgCl
 
2
 
, and 10 mM Hepes, pH 7.4. Cells were then
washed with 0.15 M NaCl before adding the anti-BrdU antibody
(B44-FITC; Becton Dickinson & Co.). After overnight incuba-
tion with anti-BrdU, cells were washed with PBS and analyzed
on the FACScan
 
Ò
 
.
 
Cell Culture.
 
Spleen cells were cultured in DMEM (GIBCO
BRL, Gaithersburg, MD) supplemented with 2 mM l-glutamine
(GIBCO BRL), 10 
 
m
 
g/ml gentamycin (GIBCO BRL), 6% FCS
(Boehringer Mannheim, Mannheim, Germany), 10 mM Hepes,
and 50 
 
m
 
M 2-ME. F5 transgenic spleen cells (5 
 
3
 
 10
 
4
 
 nucleated
cells/well) were activated in 96-well plates with various concen-
trations of nucleoprotein peptide in the presence of 2 
 
3
 
 10
 
5
 
 irra-
diated (3,000 rad) C57BL10 spleen cells in the presence or ab-
sence of 2.5% supernatant containing IL-2 (19). On day 4, cells were
pulsed for 16 h with 0.5 
 
m
 
Ci [
 
3
 
H]thymidine/well (2.0 Ci/mmol;
Amersham) and harvested on day 5 unless otherwise indicated.
For inhibition by anti-CD8 mAb (YTS 169), 1 
 
m
 
g/ml of purified
antibody was added to the cultures at the day of activation.
 
Results
 
The Majority of F5 CD8
 
1
 
 T Cells Incorporate BrdU in Re-
sponse to Peptide Challenge.
 
To determine the proportion
of CD8
 
1
 
 T lymphocytes proliferating in a primary response
to peptide, we used in vivo BrdU labeling. Results pre-
sented in Fig. 1 show that the majority of F5 spleen CD8
 
1
 
T cells incorporated BrdU in their DNA 3 d after peptide
injection. The same CD8
 
1
 
BrdU
 
1
 
 T cell population also ex-
pressed high levels of CD44. In control mice, only a small
percentage of spleen CD8
 
1
 
 T cells incorporated BrdU and
expressed CD44, consistent with the view that naive cells
are CD44
 
2
 
 noncycling cells (20). Similar results were obtained
in thymectomized and nonthymectomized animals, indi-
cating that the BrdU is incorporated in peripheral T cells 
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and not in immature thymocytes (Fig. 1). Together these
data indicate that the majority of the peripheral T cell pool
can be activated and enters the cell cycle in response to
peptide stimulation in vivo.
 
Primed CD8
 
1
 
 T Cells Are Maintained In Vivo.
 
To inves-
tigate the maintenance of primed F5 CD8
 
1
 
 T cells in vivo,
we have followed BrdU
 
1
 
 labeled peripheral CD8
 
1
 
 T cells
over time. Pulse–chase experiments were performed. Mice
were given BrdU continuously for 5 d starting 1 d before
priming. The percentage of CD8
 
1
 
 BrdU
 
1
 
 T cells was mea-
sured at different days after immunization.
Results presented in Fig. 2 
 
a
 
 show that in thymecto-
mized mice, 
 
z
 
85% of CD8
 
1
 
 T cells were still labeled with
BrdU 21 d after peptide priming. In euthymic mice, the
percentage of BrdU
 
1
 
 cells was lower (55 instead of 85%).
This difference is likely to be due to dilution by BrdU
 
2
 
thymic emigrants, because this increase in BrdU
 
2
 
 cells was
not found in thymectomized mice. In addition, these
BrdU
 
2
 
 cells expressed low levels of CD44, which corre-
lates with a naive phenotype (data not shown).
To confirm the maintenance of primed cells in an envi-
ronment where they are in competition with naive cells,
we studied their survival in euthymic mice 5 and 11 wk af-
Figure 1. In vivo BrdU incorporation by transgenic CD81 T cells after
peptide stimulation. Thymectomized and euthymic mice were either im-
munized with 50 nmol peptide on day 0 (Activated) or received only PBS
(Naive). BrdU was given in the drinking water for 4 d starting 1 d before
peptide injection. 3 d after peptide challenge, spleen cells were double
stained for BrdU and CD8 or triple stained for BrdU, CD8, and CD44.
Results for one representative mouse are shown. The percentage of
BrdU1 and BrdU2 CD81 T cells is given in the first column. The total
number (3106) of BrdU1CD81 cells is given in brackets. The expression
of CD44 by BrdU labeled cells is shown for gated CD81 T cells. Results
for one representative mouse out of two naive or four primed mice are
shown.
Figure 2. Primed CD81 T cells are long lived. The maintenance of
BrdU labeled CD8 T cells was measured at different times after peptide
stimulation and BrdU labeling. Thymectomized or euthymic mice were
either immunized with 50 nmol peptide on day 0 (primed) or received
only PBS (naive). BrdU was given in the drinking water for 5 d starting 1 d
before peptide injection. Spleen cells were double stained for BrdU and
CD8. Results for one representative mouse are shown. (a) The percent-
age of BrdU1 and BrdU2 CD81 T cells in thymectomized and euthymic
mice 21 d after peptide stimulation. (b) The percentage of BrdU1 and
BrdU2 CD81 T cells in euthymic mice 35 and 77 d after peptide prim-
ing. The total number (3106) of BrdU1CD81 cells is given in brackets.
Results for one representative mouse out of two naive or four primed
mice are shown. 
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Figure 3. Surface phenotype of primed, naive
and recently activated CD81 T cells. The expres-
sion of CD8, Vb11, CD3, CD69, IL-2Ra,
IL-2Rb, IL-2Rg, ICAM-1, LFA-1, CD45RA,
CD45RB, l-selectin, Fas, and CD5 by naive, acti-
vated, or primed CD8 spleen cells was measured by
double staining. Cells were gated for CD81 at the
acquisition level. Results for one representative
mouse out of a minimum of four are shown. (a)
CD81 T cells (- - -) from naive thymectomized
mice were compared with CD81 T cells (—) from
thymectomized mice primed 6 wk earlier. (b) CD81
T cells from naive mice (- - -) were compared with
recently activated CD81 T cells (—). Expression of
CD8, CD3, and Vb11 was measured 3 d after pep-
tide stimulation. All other markers were analyzed
on day 1.2145 Pihlgren et al.
ter priming (Fig. 2 b). The percentage of CD81BrdU1 cells
declined slowly with time. However, primed CD81BrdU1
cells still represented 20% of the total CD81 T cell popula-
tion after 80 d. Together these data show that a substantial
number of primed CD81 T cells are maintained in the
absence of division for up to 11 wk in animals in which the
thymus provides a constant supply of naive CD81 T cells
to the periphery. To avoid dilution by naive CD81 T cells,
thymectomized mice were generally used for the character-
ization of primed CD81 T cells. For activated CD81 T cells,
we used either thymectomized or euthymic mice because
in the 1st wk after priming CD81 T cells obtained in these
mice are indistinguishable in terms of phenotype or func-
tion (data not shown).
Primed CD81 T Cells Express CD44 and Ly6C. To fur-
ther characterize the surface phenotype of the primed
CD81 T cell population, we studied the expression of a
number of markers that are usually associated with an acti-
vated or memory phenotype. We saw no differences in ex-
pression of CD8, Vb11, CD3, CD69, IL-2Ra, IL-2Rb,
IL-2Rg, ICAM-1, LFA-1, CD45RA, CD45RB, l-selec-
tin, Fas, or CD5 when comparing CD81 T cells from naive
and primed mice 6 wk after peptide injection (Fig. 3 a).
However, all of these markers were up- or downregulated
on recently activated CD81 T cells 1 or 3 d after activation
(Fig. 3 b). In these experiments, CD44 was the only marker
that was upregulated by a subset of primed CD81 T cells
(Fig. 3 a).
We also measured the expression of Ly6C, which has
been described by others as a good marker for memory
CD81 T cells (21). Using triple staining for CD8, CD44,
and Ly6C, we found that a large proportion of primed
CD81 T cells expressed intermediate levels of CD44 and
high levels of Ly6C in peptide primed thymectomized
mice (Fig. 4 a). This CD44intLy6Chigh CD81 T cell popula-
tion was not seen in naive thymectomized animals. Ly6C
was also not expressed by recently activated CD81 T cells,
which have already upregulated CD44 (Fig. 4 a). In addi-
tion to these cells, a CD81CD44highLy6Chigh T cell popula-
tion was detected in primed and naive thymectomized
mice. These cells also expressed a large number of the other
activation markers (data not shown). Their origin is un-
known, but peptide priming is not necessary for their gen-
eration because they are also present in naive mice. These
Figure 4. Expression of Ly6C and CD44 by naive, activated, or primed CD81 T cells. (a) Spleen cells from thymectomized mice primed 5 wk earlier
or from naive thymectomized mice and from euthymic mice primed 1 d earlier (activated) or from naive euthymic mice (naive) were triple stained for
CD44, Ly6C, and CD8. Cells were gated for CD81 at the acquisition level. The expression of CD44 and Ly6C is shown. The percentage of CD81 cells
expressing intermediate levels of CD44 and intermediate to high levels of Ly6C is given. The total number (3106) of CD81CD44intLy6Chigh cells is given
in brackets. Results for one mouse out of a minimum of three are shown. (b) The expression of CD44 and Ly6C by BrdU1CD81 T cells from primed
euthymic mice (—) was measured 11 wk after peptide stimulation. The CD81 BrdU2 T cells (- - -) from the same mice are shown as a control. CD8
cells were labeled with BrdU for 5 d starting 1 d before peptide stimulation. Cells were gated for CD81BrdU2 or CD81BrdU1 at the acquisition level.
Results are shown for two mice per group.2146 Generation of Resting, Hyperreactive Memory CD81 T Cells
results indicate that CD44intLy6Chigh CD81 T cells are the
major subset of primed cells generated in this system.
The phenotype of primed CD81 T cells found in thy-
mectomized mice was confirmed in euthymic mice. CD81
T cells from euthymic mice primed and pulsed with BrdU
11 wk earlier were triple stained for CD8, BrdU, and CD44
or Ly6C. Data presented in Fig. 4 b confirm that primed CD81
BrdU1 T cells expressed increased levels of CD44 and Ly6C.
Figure 5. In vivo primed CD81 T cells are responsive to secondary challenge with peptide. (a) Experimental plan of the in vivo CD81 T cells restim-
ulation. (b) 1 d after peptide stimulation, spleen cells were double stained for CD8 and CD69 or CD8 and CD44. The cell size of CD81 T cells as well
as the expression of CD69 or CD44 by these cells are shown. Results for one naive and two primed mice are shown. (c) The percentage of CD81 T cells
proliferating in response to peptide challenge was measured by BrdU incorporation. Spleen cells were double stained for BrdU and CD8. The percentage
of BrdU1 and BrdU2 CD81 T cells is given. The total number (3106) of BrdU1CD81 cells is given in brackets. Results for one representative mouse
out of two are shown.2147 Pihlgren et al.
These results confirm that in this system, primed CD81
T cells are noncycling and can be phenotypically distin-
guished from naive or freshly activated CD81 T cells by dif-
ferential expression of the surface markers CD44 and Ly6C.
Primed CD81 T Cells Can Be Reactivated In Vivo. Because
in some systems peptide challenge can also lead to anergy
(22), we studied the in vivo response to peptide of primed
CD81 T lymphocytes. Primed and naive thymectomized
mice were challenged with peptide as described in Fig. 5 a,
and the changes of surface phenotype as well as the prolif-
eration of CD81 T cells were measured.
Resting naive and primed CD81 T cells expressed simi-
lar levels of CD69 and had a low forward scatter profile. In
contrast, as previously shown, primed CD81 T cells ex-
pressed intermediate levels of CD44. 1 d after peptide chal-
lenge, all CD81 T cells from primed or naive mice became
blast size and upregulated the early activation marker CD69
as well as CD44 (Fig. 5 b), indicating that the majority of
CD81 T cells are stimulated by the peptide.
We next determined whether cells from primed mice
proliferated in vivo. Primed and naive thymectomized
mice were injected with peptide, and dividing cells were
labeled with BrdU. The proportion of CD81BrdU1 T cells
was determined 6 d later. Results presented in Fig. 5 c
show that the same proportion of naive and primed CD81
T cells incorporated BrdU in response to peptide challenge
(73 and 75%, respectively). In contrast, in the absence of
peptide challenge, only a small fraction of naive and primed
splenic T cells incorporated BrdU (15 and 8%, respectively)
and these cells were essentially all CD44high cells (data not
shown). This observation further supports results discussed
above that suggest that similarly to naive CD81 T cells,
primed CD44intCD81 T cells are slowly or noncycling cells.
Together, these results show that the majority of primed
CD81 T cells are not anergic because they respond to pep-
tide restimulation in vivo.
Primed CD81 T Cells Are Hyperreactive to Peptide In Vitro.
We have compared the activation threshold of naive and
Figure 6. In vitro proliferative responses of CD8 T cells from primed and naive thymectomized mice. (a) 5 3 104 spleen cells were activated with dif-
ferent concentrations of peptide in the presence or absence of IL-2 as described in Materials and Methods. Cell proliferation was measured by [3H]thymi-
dine uptake after 4 d in culture. Results for two mice per group are shown. The percentages of CD81 T cells in the spleen of primed or naive mice were
comparable, 23 and 17% versus 21 and 18%, respectively. This experiment was performed at least four times with similar results. (b) The proliferation rate
of primed and naive CD81 T cells was measured at different times after activation with 0.1 nM peptide in the presence of IL-2. (c and d) The activation
of CD81 T cells by different concentrations of peptide was inhibited by anti-CD8 mAb (1 mg/ml final concentration in the wells). Proliferation was mea-
sured after 4 d of culture. The proliferative response of one naive and one primed mouse in the presence or absence of anti-CD8 mAb is shown in c. The
percentage inhibition in the presence of anti-CD8 antibodies was calculated for each dose of peptide from the following formula: ([proliferation in the
absence of anti-CD8 2 proliferation in the presence of anti-CD8]/proliferation in the absence of anti-CD8) 3100. The percentage inhibition for two
naive and two primed mice is shown in d.2148 Generation of Resting, Hyperreactive Memory CD81 T Cells
primed CD81 T cells in vitro. Spleen cells from naive and
primed mice were activated with different peptide concen-
trations, and proliferation was measured by thymidine up-
take. In the absence of IL-2, naive and primed cells prolif-
erated equally well in response to a range of peptide doses
(Fig. 6 a). In the presence of IL-2, both cell populations
were activated by lower peptide concentrations. However,
in these conditions, primed cells responded to lower doses
of peptide and showed a stronger proliferative capacity than
their naive counterparts.
To verify that the hyperreactivity in the presence of IL-2
was not due to different kinetics of proliferation, we moni-
tored thymidine incorporation at different days after in
vitro peptide stimulation. As can be seen in Fig. 6 b,
primed cells were hyperreactive to peptide during the en-
tire duration of the culture.
In other CD8 systems, in vitro proliferation or cytolytic
activity of naive CTL precursors was inhibited by an anti-
CD8 mAb, whereas primed CTL precursors were resistant to
anti-CD8 inhibition (23, 24). We therefore tested the in-
hibitory effect of anti-CD8 antibodies on the CD81 T cell
proliferative response to peptide in the presence of IL-2.
Results presented in Fig. 6, c and d, show that primed
CD81 T lymphocytes are more resistant to anti CD8 mAb
inhibition than naive cells at high antigen concentrations.
At lower concentrations of peptide, both naive and primed
cells were completely inhibited. These results show that in
the presence of IL-2, primed CD81 T cells have a lower
stimulation threshold than naive CD81 T cells. Finally, be-
cause the hyperreactivity of primed CD81 T cells was de-
pendent on the presence of IL-2, it was possible that the
expression of IL-2R was differentially regulated in naive
and primed CD81 T cells. The responsiveness of T cells to
IL-2 is mainly regulated through the expression of IL-2Ra
(25). Therefore, we measured the expression of the IL-2Ra
chain by primed and naive CD81 T cells after in vitro acti-
vation by peptide. Fig. 7 shows that 21 h after activation,
the majority of naive or primed CD81 T cells have up-
regulated their IL-2Ra chain. This is followed by a fur-
ther increase in IL-2Ra chain expression, with primed
cells showing a more rapid upregulation than naive CD81
T cells. Indeed, after 2 d of culture 25% of primed cells
compared with 8% of naive cells have already further up-
regulated their IL-2Ra chain. A similar but only transient
upregulation of the IL-2Ra chain was observed when
CD81 T cells were activated in the absence of IL-2, sug-
gesting that the maintenance of high levels of IL-2Ra
chain expression is dependent on IL-2. These results indi-
cate that the hyperreactivity of primed CD81 T cells in the
presence of IL-2 correlates with a more rapid upregulation
of the IL-2Ra chain by these cells.
Discussion
We have described an experimental system in which a
population of resting primed CD81 T cells can be gener-
ated in vivo. These CD81 T cells express a defined pheno-
type different from naive or recently activated CD81 T cells,
are capable of responding to peptide in vivo, and are hy-
perreactive to antigen in vitro.
TCR transgenic mice or peptide immunization have
been used with mixed success to study the differentiation of
memory T cells in vivo. Although peptides have been used
successfully to induce CD8-mediated immunity in several
systems (26–29), they have also been shown to induce un-
responsiveness rather than immunity (22). A number of
parameters could account for these differences. First, differ-
ent affinities of peptide for MHC and TCR for peptide–
MHC complexes could influence the level of T cell trigger-
ing, which in turn might play a role in the fate of activated
T cells (30). This has been clearly illustrated for CD41 T cells
by Liblau and colleagues (31), who have shown in two dif-
ferent strains of TCR transgenic mice that opposite results
are obtained with different peptides but similar immuniza-
tion protocols.
Second, the route of administration as well as the use of
adjuvant has also been shown to influence the outcome of
the response (27, 32). In the F5 system, we have tested dif-
ferent routes of peptide delivery (i.e., intraperitoneal, in
NaCl, intraperitoneal in IFA, or subcutanously in CFA)
and have not found any differences in the changes of phe-
notype of spleen or LN CD81 T cells during the primary
response (data not shown). This indicates that in F5 TCR
transgenic mice, the TCR used leads to CD81 T cell acti-
vation by peptide independently of the immunization route.
Figure 7. Expression of IL-2Ra on naive and primed CD81 T cells
after activation with peptide in vitro. 106 spleen cells were activated with
1 nM peptide in the presence or absence of 2.5% IL-2. Expression of
IL-2Ra by CD81 T cells was measured by double staining after 21, 45,
or 69 h of stimulation. Cells were gated for CD81 at the acquisition level.
The results for two representative naive (....) or primed mice (—) out of
six are shown. Fresh resting CD81 T cells from a naive mouse were used
as a negative control ( ). .–.–.2149 Pihlgren et al.
For CD41 T cells, it has been reported that primed cells
generated by in vivo immunization of TCR transgenic
mice differ from CD41 cells primed in a polyclonal envi-
ronment (5). We have successfully used the F5 TCR trans-
genic mice to generate a peptide primed CD81 T cell pop-
ulation that shows in vitro hyperreactivity to peptide.
These cells express levels of CD44 and Ly6C that differen-
tiate them not only from naive transgenic CD81 T cells but
also from freshly activated transgenic CD81 T cells. This is
in agreement with the phenotype of memory CD81 T cells
obtained in other systems (21, 23). In contrast, l-selectin is
expressed by our primed CD81 T cells. In other systems,
this marker is downregulated by primed CD81 T cells (7,
33), although in some systems a population of l-selectin1
primed CD81 T cells is also found (10, 33). This indicates
that phenotypically different subsets of primed CD81 T cells
can be generated in vivo. Such a heterogeneity is also
found when the cell cycle status or the ex vivo CTL activ-
ity of primed CD81 T cells is studied (9). Up to now it has
not been possible to match up these different properties of
primed CD81 T cells. This is mainly due to the fact that in
most systems cells that were primed in the course of the
primary response cannot be traced and identified later on.
Moreover, antigen priming quite often leads to a mixed
population of primed cells in terms of phenotype, cell cycle
status, or function. The advantage of the system we de-
scribe is that it allows the characterization of one subset of
primed CD81 T cells that may contribute to the memory
response. These resting primed CD81 T cells are not a
transgenic artefact, because CD81 T cells with a similar
phenotype (i.e., CD44int) and cell cycle status have been
described in nontransgenic animals (9). However, these non-
transgenic cells have not been characterized functionally.
A population of CD44highLy6ChighCD81 cells was also
observed in thymectomized TCR transgenic mice (see Fig.
4 a). These cells are also found in nonthymectomized mice,
where they represent a minority of CD81 T cells (,5% or
0.5–1.0 3 106 cells per spleen). After thymectomy there is
a three to five-fold increase in the number of these cells
whether the mice have been primed or not, indicating that
the expansion of this population is independent of peptide
priming. These cells show a phenotype similar to recently
activated cells (i.e., they are CD8low, Vb11low, CD3low,
IL-2Rbhigh, ICAM-1high, LFA-1high; data not shown), and
in vivo they proliferate more than naive T cells, adding to
the hypothesis that they are activated CD81 T cells (see
Fig. 1, CD44 versus BrdU in naive animals). The origin of
these cells as well as the ligand that drives their proliferation
are not known. Some of these cells could express a second
receptor. However, because cells with a similar phenotype
also exist in F5 mice back-crossed to a Rag2/2 back-
ground, it is likely that at least a subset of them only express
the F5 TCR.
Primed cells generated in vivo after immunization with
peptide were not anergic, because their response to peptide
rechallenge was indistinguishable from the response of na-
ive cells in terms of phenotype or proliferation. In these in
vivo experiments, primed cells did not show increased pro-
liferation compared with naive cells. This could be due to
the experimental conditions because the amount of peptide
used to prime mice is 10–50-fold higher than the mini-
mum needed to activate all CD81 T cells in vivo (based on
CD44 upregulation). Therefore it is possible that primed
CD81 T cells could respond differently from naive CD81
T cells if mice were immunized with suboptimal doses of
peptide.
The activation threshold of naive and primed cells was
compared in vitro. In the absence of IL-2, naive and
primed cells were activated by the same peptide concentra-
tions and proliferated to the same extent. In contrast, in the
presence of IL-2, the activation of naive cells was signifi-
cantly increased, indicating that F5 CD81 T cells are helper
dependent at low peptide concentrations. More notable,
under the same culture conditions, primed cells showed a
strong hyperreactivity to peptide because they responded to
peptide concentrations 10–50-fold lower than those re-
quired to activate naive T cells. The increased proliferation
of primed cells was not due to the sole action of IL-2 be-
cause they did not express detectable levels of IL-2 recep-
tors or proliferate to IL-2 in the absence of peptide. T cell
responsiveness to IL-2 is mainly regulated via the expres-
sion of the IL-2Ra chain (25). This expression is initiated
by TCR engagement and can be upregulated by IL-2 and a
number of other interleukins or costimulatory molecules
(25, 34–36). The expression of IL-2Ra chain by primed
and naive T cells was measured at different times after acti-
vation. A similar increase in IL-2Ra chain expression was
observed in both populations after 24 h of culture. How-
ever, further upregulation was more efficient on primed
cells. These results are difficult to interpret because the ex-
periments we have performed do not allow us to determine
if the increased efficiency in Il-2Ra chain expression by
primed cells is the cause or the consequence of the primed
CD81 T cells’ hyperreactivity. However, they indicate that
the initial IL-2Ra induction by the TCR is similar in naive
and primed cells. The in vitro hyperreactivity of primed
CD81 T cells could result either from a different coupling
of the TCR and/or from an overall increased avidity after
the upregulation of CD44, Ly6C, or other molecules. Dif-
ference in the coupling of TCR has been demonstrated for
anergic T cells, where the activation threshold is signifi-
cantly increased after uncoupling of the TCR from the ras-
raf-MapK pathway (37, 38). The CD44 and Ly6C upregu-
lation could also be part of the hyperreactive phenotype
because both molecules are able to costimulate T cells (39,
40). These different hypotheses are currently being tested.
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